Dr. Priyank P. Patel
Claim this profileCarle Cancer Center
Expert in Cancer
Studies Lung Cancer
27 reported clinical trials
67 drugs studied
About Priyank P. Patel
Education:
- Obtained MD from the University of Illinois College of Medicine at Peoria in 2015.
- Completed Residency in Radiation Oncology at the University of Iowa Hospitals and Clinics in 2020.
- Finished Fellowship in Stereotactic Body Radiotherapy (SBRT) and Stereotactic Radiosurgery (SRS) at the University of California, San Francisco in 2021.
Experience:
- Specializes in Radiation Oncology, Stereotactic Body Radiotherapy (SBRT), and Stereotactic Radiosurgery (SRS).
- Associated with Carle Cancer Center.
Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Lung Cancer
Stage IV
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Priyank P. Patel is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
More about Priyank P. Patel
Clinical Trial Related5 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Priyank P. Patel has experience with
- Carboplatin
- Atezolizumab
- Cisplatin
- Nivolumab
- Pembrolizumab
- Venetoclax
Breakdown of trials Priyank P. Patel has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Priyank P. Patel specialize in?
Priyank P. Patel focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage II.
Is Priyank P. Patel currently recruiting for clinical trials?
Yes, Priyank P. Patel is currently recruiting for 10 clinical trials in Urbana Illinois. If you're interested in participating, you should apply.
Are there any treatments that Priyank P. Patel has studied deeply?
Yes, Priyank P. Patel has studied treatments such as Carboplatin, Atezolizumab, Cisplatin.
What is the best way to schedule an appointment with Priyank P. Patel?
Apply for one of the trials that Priyank P. Patel is conducting.
What is the office address of Priyank P. Patel?
The office of Priyank P. Patel is located at: Carle Cancer Center, Urbana, Illinois 61801 United States. This is the address for their practice at the Carle Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.